Global Systemic Lupus Erythematosus Market by Drug Class (NSAIDs, Biologics, Immunosuppressants, Antimalarials, Corticosteroids) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Industry Insights
In 2017, the global market for systemic lupus, erythematosus was valued at USD 1.87 million. The market is expected to grow at 7.0% during the forecast period. Market growth is expected to accelerate with the arrival of key pipeline agents that promise greater efficacy than existing therapies.
The treatment of autoimmune conditions is much more effective with biologics and doctors are increasingly trusting them. The FDA and EMA approved Benlysta in 2011, the first biologic approved in the last 50 years. In 2011, the FDA and EMA approved Benlysta. Market adoption of Benlysta is hindered by its low to moderate efficacy in treating patients with severe systemic Lupus Erythematosus (SLE), and Lupus Nephritis. GSK is conducting clinical trials to assess the efficacy of Benlysta combined with rituximab in order to increase market adoption.
Some of the pipeline biologics currently undergoing phase III clinical trials will be available for sale in 2018-2021. The European League against Rheumatism, which sets guidelines for reimbursement for therapies, defines the eligibility for biologics on the market.
These guidelines state that physicians must only prescribe biologics to patients if two or more non-biologic immunesuppressants fail to improve the disease activity. These guidelines have been used by many countries to determine their reimbursement policies. They vary greatly. The higher demand for Benlysta is due to the availability of healthcare services and better coverage. In contrast, in developing countries, access to biologics is limited by high costs and a lack of government-funded coverage.
Drug Class Insights
In 2017, the largest revenue share was held by immunosuppressants, which was valued at USD 1.01 million. Methotrexate is widely used worldwide, and this has contributed to the growth of the market. Biologics was placed after the segment due to Benlysta's slow penetration.
Biologics will see the highest CAGR at 12.0% over the forecast period. The market will grow if new biologics are introduced with better efficacy. Benlysta, the first approved on-label SLE biologic, has been a success with mild to moderate SLE. For severe forms of SLE, however, safety and efficacy are still being evaluated. Other biologic agents, such as rituximab, can be used off-label to treat systemic lupus. They are not as dangerous as immunosuppressants and corticosteroids.
Route of Administration Insights
In 2017, the oral segment accounted for more than half the total value of the SLE market. In 2017, the segment was closely followed by intravenous (which accounted for just 35.0%). Small molecule drugs are easy to administer and continue to be the main treatment for SLE.
The forecast period sees the subcutaneous segment growing at a 10.4% CAGR. One of the main growth stimulants in the subcutaneous segment is the recent approval of Benlysta and Rituximab subcutaneous formulations in many countries, including the U.S.A and several European countries. These formulations allow patients to self-administrate these therapies which increases prospects for this segment.
Regional Insights
The market was dominated by North America in 2017, with the U.S. leading the charge. It is expected to maintain its leadership position until 2025 with a CAGR 8.1% over the forecast period. The region's market is growing due to a higher prevalence of SLE and better coverage for specialty drugs, as well as a better healthcare infrastructure.
Europe was the second largest regional market in 2017, with a value of USD 397.6 millions. It can be attributed that Benlysta was approved by five European Union countries: the U.K. Germany Spain Italy France and Spain. Due to its availability in both forms, belimumab is more commonly used because of better coverage policies.
LATAM, APAC, and MEA are the least prominent in the market. These regions have low revenue generation due to a variety of factors. The lowest rheumatologist-to-population ratio can also be blamed for preventing early diagnosis and treatment. Patients are not able to access belimumab, even though it is available in these areas. Patients in low-income countries often seek out the public health system, which is not equipped to provide quality medical care.
SLE Market Share Information
GlaxoSmithKline is the market leader, followed by Roche, Pfizer and Novartis. Bayer and Sanofi are also prominent players. GlaxoSmithKline is conducting clinical trials for Benlysta as well as rituximab in collaboration with Roche to evaluate their combined effectiveness in treating severe SLE symptoms. Novartis also developed a biosimilar of rituximab that is affordable and can be used to promote the use of biologic therapies in developing countries.
Manufacturers focus their strategic efforts on developing biologics that are more effective. Aurinia Pharmaceuticals and Astra Zeneca will be launching promising therapies in the near future, including Lupuzor and Voclosporin.
Report Scope
Attribute |
More Details |
Estimation base year |
2017 |
Actual estimates/Historical data |
2014 - 2016 |
Forecast period |
2018 - 2025 |
Representation of the market |
From 2018 to 2025, revenue in USD million and CAGR |
Regional scope |
North America, Europe and Asia Pacific, LATAM and MEA |
Country coverage |
U.S., Canada, U.K., Germany, France, Italy, Spain, Greece, Sweden, Norway, Poland, Japan, China, Hong Kong, Taiwan, South Korea, New Zealand, Australia, India, Malaysia, Singapore, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, Turkey, Kuwait, and Israel |
Report coverage |
Trends, revenue, company share, competitive landscape and growth factors |
15% off customization scope (equivalent of 5 analysts working day) |
We will customize the report to provide you with any additional information that you require. |
The Report Covers Certain Segments
This report predicts revenue growth at the global, regional and country levels. It also provides analysis of industry trends in each sub-segment from 2014 to 2025. Up Market Research has divided the global systemic Lupus Erythematosus market report by drug classes, route and region.
-
The Outlook for Drug Classes (Revenue, USD million, 2014-2025)
-
NSAIDs
-
Corticosteroids
-
Antimalarials
-
Immunosuppressants
-
Biologics
-
-
Route of Administration Outlook (Revenue USD Million, 2014 - 2025).
-
Oral
-
Intravenous
-
Subcutaneous
-
-
Regional Outlook (Revenue USD Million, 2014-2025)
-
North America
-
The U.S.
-
Canada
-
-
Europe
-
The U.K.
-
Germany
-
France
-
Italy
-
Spain
-
Greece
-
Sweden
-
Norway
-
Poland
-
E
-
-
Asia Pacific
-
Japan
-
China
-
Hong Kong
-
Taiwan
-
South Korea
-
New Zealand
-
Australia
-
India
-
Malaysia
-
Singapore
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
-
MEA
-
Turkey
-
Saudi Arabia
-
Kuwait
-
Israel
-
South Africa
-
-
Up Market Research published a new report titled “Systemic Lupus Erythematosus Market research report which is segmented by Drug Class (NSAIDs, Biologics, Immunosuppressants, Antimalarials, Corticosteroids), By Players/Companies GlaxoSmithKline in collaboration with Roche is conducting clinical trials with Benlysta and rituximab to determine their combined efficacy in treating severe symptoms of SLE Furthermore, Novartis developed a biosimilar rituximab at a low cost, Roche, Pfizer, GlaxoSmithKline, Sanofi Among key strategies, which is used as an off label drug to fuel the adoption of biological therapies in developing regions, Novartis, Bayer”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
Report Attributes | Report Details |
Report Title | Systemic Lupus Erythematosus Market Research Report |
By Drug Class | NSAIDs, Biologics, Immunosuppressants, Antimalarials, Corticosteroids |
By Companies | GlaxoSmithKline in collaboration with Roche is conducting clinical trials with Benlysta and rituximab to determine their combined efficacy in treating severe symptoms of SLE Furthermore, Novartis developed a biosimilar rituximab at a low cost, Roche, Pfizer, GlaxoSmithKline, Sanofi Among key strategies, which is used as an off label drug to fuel the adoption of biological therapies in developing regions, Novartis, Bayer |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 241 |
Number of Tables & Figures | 169 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Systemic Lupus Erythematosus Market Report Segments:
The market is segmented by Drug Class (NSAIDs, Biologics, Immunosuppressants, Antimalarials, Corticosteroids).
Systemic Lupus Erythematosus Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Systemic Lupus Erythematosus Market
Overview of the regional outlook of the Systemic Lupus Erythematosus Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Systemic Lupus Erythematosus Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Systemic Lupus Erythematosus Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. NSAIDs
2. Biologics
3. Immunosuppressants
4. Antimalarials
5. Corticosteroids
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Lupus Erythematosus Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Systemic Lupus Erythematosus Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Systemic Lupus Erythematosus Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Systemic Lupus Erythematosus Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Systemic Lupus Erythematosus Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Systemic Lupus Erythematosus Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Systemic Lupus Erythematosus Market Size & Forecast, 2018-2028
4.5.1 Systemic Lupus Erythematosus Market Size and Y-o-Y Growth
4.5.2 Systemic Lupus Erythematosus Market Absolute $ Opportunity
Chapter 5 Global Systemic Lupus Erythematosus Market Analysis and Forecast by Drug Class
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Drug Class
5.1.2 Basis Point Share (BPS) Analysis by Drug Class
5.1.3 Absolute $ Opportunity Assessment by Drug Class
5.2 Systemic Lupus Erythematosus Market Size Forecast by Drug Class
5.2.1 NSAIDs
5.2.2 Biologics
5.2.3 Immunosuppressants
5.2.4 Antimalarials
5.2.5 Corticosteroids
5.3 Market Attractiveness Analysis by Drug Class
Chapter 6 Global Systemic Lupus Erythematosus Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Systemic Lupus Erythematosus Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Systemic Lupus Erythematosus Analysis and Forecast
8.1 Introduction
8.2 North America Systemic Lupus Erythematosus Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Systemic Lupus Erythematosus Market Size Forecast by Drug Class
8.6.1 NSAIDs
8.6.2 Biologics
8.6.3 Immunosuppressants
8.6.4 Antimalarials
8.6.5 Corticosteroids
8.7 Basis Point Share (BPS) Analysis by Drug Class
8.8 Absolute $ Opportunity Assessment by Drug Class
8.9 Market Attractiveness Analysis by Drug Class
Chapter 9 Europe Systemic Lupus Erythematosus Analysis and Forecast
9.1 Introduction
9.2 Europe Systemic Lupus Erythematosus Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Systemic Lupus Erythematosus Market Size Forecast by Drug Class
9.6.1 NSAIDs
9.6.2 Biologics
9.6.3 Immunosuppressants
9.6.4 Antimalarials
9.6.5 Corticosteroids
9.7 Basis Point Share (BPS) Analysis by Drug Class
9.8 Absolute $ Opportunity Assessment by Drug Class
9.9 Market Attractiveness Analysis by Drug Class
Chapter 10 Asia Pacific Systemic Lupus Erythematosus Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Systemic Lupus Erythematosus Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Systemic Lupus Erythematosus Market Size Forecast by Drug Class
10.6.1 NSAIDs
10.6.2 Biologics
10.6.3 Immunosuppressants
10.6.4 Antimalarials
10.6.5 Corticosteroids
10.7 Basis Point Share (BPS) Analysis by Drug Class
10.8 Absolute $ Opportunity Assessment by Drug Class
10.9 Market Attractiveness Analysis by Drug Class
Chapter 11 Latin America Systemic Lupus Erythematosus Analysis and Forecast
11.1 Introduction
11.2 Latin America Systemic Lupus Erythematosus Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Systemic Lupus Erythematosus Market Size Forecast by Drug Class
11.6.1 NSAIDs
11.6.2 Biologics
11.6.3 Immunosuppressants
11.6.4 Antimalarials
11.6.5 Corticosteroids
11.7 Basis Point Share (BPS) Analysis by Drug Class
11.8 Absolute $ Opportunity Assessment by Drug Class
11.9 Market Attractiveness Analysis by Drug Class
Chapter 12 Middle East & Africa (MEA) Systemic Lupus Erythematosus Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Systemic Lupus Erythematosus Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Systemic Lupus Erythematosus Market Size Forecast by Drug Class
12.6.1 NSAIDs
12.6.2 Biologics
12.6.3 Immunosuppressants
12.6.4 Antimalarials
12.6.5 Corticosteroids
12.7 Basis Point Share (BPS) Analysis by Drug Class
12.8 Absolute $ Opportunity Assessment by Drug Class
12.9 Market Attractiveness Analysis by Drug Class
Chapter 13 Competition Landscape
13.1 Systemic Lupus Erythematosus Market: Competitive Dashboard
13.2 Global Systemic Lupus Erythematosus Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 GlaxoSmithKline in collaboration with Roche is conducting clinical trials with Benlysta and rituximab to determine their combined efficacy in treating severe symptoms of SLE Furthermore
13.3.2 Novartis developed a biosimilar rituximab at a low cost
13.3.3 Roche
13.3.4 Pfizer
13.3.5 GlaxoSmithKline
13.3.6 Sanofi Among key strategies
13.3.7 which is used as an off label drug to fuel the adoption of biological therapies in developing regions
13.3.8 Novartis
13.3.9 Bayer